Zai

Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates

Retrieved on: 
Thursday, March 19, 2020
Zai, Ovarian cancer

Coinciding with the celebration of our five-year anniversary, 2019 was a year of many important achievements for Zai Lab, said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab.

Key Points: 
  • Coinciding with the celebration of our five-year anniversary, 2019 was a year of many important achievements for Zai Lab, said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab.
  • In December 2019, Zai Lab announced that the China NMPA approved the NDA for ZEJULA as maintenance treatment of patients with recurrent ovarian cancer.
  • In November 2019, Zai Lab completed enrollment of the China Phase 3 PRIME study of ZEJULA in patients with first-line ovarian cancer.
  • In December 2019, Zai Lab announced the appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board.

Zai Lab to Announce Financial Results for the Full Year Ended December 31, 2019 and Corporate Updates on March 19, 2020

Retrieved on: 
Thursday, March 5, 2020
Zai

ET

Key Points: 
  • ET
    SHANGHAI, China and SAN FRANCISCO, March 05, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced it will report financial results for the full year ended December 31, 2019 and corporate updates before the market opens on Thursday, March 19, 2020 and host a conference call at 8:30 a.m.
  • On the call, Zai Labs senior management team will also provide an update on the Companys business and upcoming milestones.
  • The live webcast and a replay may be accessed by visiting the Companys website at http://ir.zailaboratory.com.
  • Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.

Zai Lab Announces Upcoming Participation at February Conferences

Retrieved on: 
Tuesday, February 11, 2020
Zai

SHANGHAI, China and SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder and Chief Executive Officer, will be presenting at the following upcoming conferences in February.

Key Points: 
  • SHANGHAI, China and SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder and Chief Executive Officer, will be presenting at the following upcoming conferences in February.
  • Details of the conferences are as follows:
    Live webcasts of the conferences will be available under "Events & Presentations in the Investors Relations section of Zai Labs website.
  • Zai Lab (NASDAQ: ZLAB) is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.
  • Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.

Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA

Retrieved on: 
Monday, February 10, 2020
Articles, Health, Life sciences, Pharmacy, Pharmaceutical industry, Pharmaceuticals policy, National Music Publishers Association, Antimicrobial resistance, Biopharmaceutical, Zai, Drug

This is another important step in the development of Zai as a fully-integrated biopharmaceutical company, said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab.

Key Points: 
  • This is another important step in the development of Zai as a fully-integrated biopharmaceutical company, said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab.
  • This NDA is our third submission accepted for review by the China NMPA and our first anti-infective NDA and demonstrates our capabilities in therapeutic areas outside of oncology.
  • There are limited treatment options against drug-resistant bacteria in China, and omadacycline is an innovative drug that can address such unmet medical needs.
  • Zais omadacycline filing with the NMPA was accepted as a Category 1 drug and omadacycline will be locally manufactured in China.

Zai Lab Announces Proposed Public Offering of American Depositary Shares

Retrieved on: 
Tuesday, January 21, 2020
ADSS, American depositary receipt, Zai

SHANGHAI, China, and SAN FRANCISCO, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab or the Company) (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 5,500,000 American depositary shares (ADSs), each representing one ordinary share of the Company (the Primary ADS Offering).

Key Points: 
  • SHANGHAI, China, and SAN FRANCISCO, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab or the Company) (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 5,500,000 American depositary shares (ADSs), each representing one ordinary share of the Company (the Primary ADS Offering).
  • In addition, QM11 Limited, a shareholder of the Company, intends to offer 500,000 ADSs of the Company (the Secondary ADS Offering and together with the Primary ADS Offering, the Offering).
  • Zai Lab and QM11 Limited expect to grant the underwriters a 30-day option to purchase up to 800,000 and 100,000 additional ADSs, respectively.
  • Zai Lab will not receive any proceeds from the sale of the ADSs by QM11 Limited.

Zai Lab Appoints Lonnie Moulder to Board of Directors

Retrieved on: 
Tuesday, January 14, 2020
Zai, Trevena

SHANGHAI, China and SAN FRANCISCO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the appointment of Lonnie Moulder to its Board of Directors.

Key Points: 
  • SHANGHAI, China and SAN FRANCISCO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the appointment of Lonnie Moulder to its Board of Directors.
  • "We are delighted to welcome Lonnie Moulder to our Board of Directors," said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab.
  • I am excited to work with Zais leadership team and fellow directors as the Company rapidly progresses to a leading, fully-integrated biopharmaceutical company, said Mr. Moulder.
  • In addition to serving on the Board of Directors of Zai Lab, Mr. Moulder currently serves on the Board of Directors of Aegle Therapeutics, Dianthus Therapeutics, TamuroBio and Trevena.

Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board

Retrieved on: 
Monday, December 16, 2019
Zai, Dr. Yap

SHANGHAI, China and SAN FRANCISCO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board (SAB).

Key Points: 
  • SHANGHAI, China and SAN FRANCISCO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board (SAB).
  • Dr. Yap will advise Zai Lab as the Company prepares to advance its internally discovered therapeutics into the clinic.
  • We are excited to have Dr. Yap join our SAB, said Dr. Valeria Fantin, Chief Scientific Officer of Zai Lab.
  • These forward-looking statements should not be relied upon as representing Zai Labs views as of any date subsequent to the date of this press release.

Zai Lab Announces Upcoming Presentations at November Conferences

Retrieved on: 
Wednesday, October 30, 2019
Zai

SHANGHAI, China and SAN FRANCISCO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of the senior management team will be presenting at the following upcoming conferences this November.

Key Points: 
  • SHANGHAI, China and SAN FRANCISCO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (Zai Lab) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of the senior management team will be presenting at the following upcoming conferences this November.
  • Details of the conferences are as follows:
    A live webcast of the Jefferies 2019 London Healthcare Conference presentation will be available under Events & Presentations in the Investor Relations section of Zai Labs website.
  • Zai Lab (NASDAQ: ZLAB) is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.
  • Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners' and its own products in order to impact human health worldwide.

Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference

Retrieved on: 
Friday, October 4, 2019
Zai

SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder and Chief Executive Officer, will speak at the Forbes Global CEO Conference being held on October 15-16, 2019, in Singapore.

Key Points: 
  • SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder and Chief Executive Officer, will speak at the Forbes Global CEO Conference being held on October 15-16, 2019, in Singapore.
  • Now in its 19th year, the prestigious Conference is an annual gathering for more than 400 global CEOs, entrepreneurs, investors and thought leaders to discuss and debate key issues of global concern and to build new partnerships.
  • Under the theme Transcending the Turbulence, this years Conference will examine how CEOs, companies and countries are navigating the challenges and opportunities arising from thecurrent state of the global economy.
  • Zai Lab (ZLAB) is a China and U.S.-based innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.

Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019

Retrieved on: 
Tuesday, September 3, 2019
Zai

With a growing pipeline and execution progress, Zai Lab has established a global reputation as a China biotech pioneer.

Key Points: 
  • With a growing pipeline and execution progress, Zai Lab has established a global reputation as a China biotech pioneer.
  • We expect the upcoming months to potentially be transformative for Zai Lab as we prepare for the marketing approvals for ZEJULA and Optune in China.
  • In June 2019, Zai Lab announced receipt of marketing authorization to commercialize ZEJULA in Macau for women with relapsed ovarian cancer.
  • Zai Lab will host a live conference call and webcast today, September 3, 2019 at 8:30 a.m. EDT to review its financial results and provide a general business update.